Insitro
Combines machine learning and high-throughput biology to transform drug discovery.
What they do
Insitro uses machine learning and high-throughput biology to generate massive datasets and build predictive models of human disease. The platform is used by internal therapeutic teams and pharmaceutical partners to discover novel targets and design therapeutics for metabolic and neurodegenerative diseases.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- South San Francisco, USA
- Region
- North America
- Founded
- 2018
- Total funding
- $743M raised
Notable investors: Andreessen Horowitz, Canada Pension Plan Investment Board, ARCH Venture Partners, Foresite Capital.